Advanced Filters
noise

Dementia Clinical Trials

A listing of Dementia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 807 clinical trials
D DUMURGIER Julien, MD, PhD

Donepezil Versus Non-drug Treatment in Alzheimer's Disease.

Donepezil, as well as the other symptomatic drugs of Alzheimer's disease, is not any more reimbursed by the French healthcare system, due to a controversy about its efficiency. French health authorities currently preconize a non-rug approach based on cognitive remediation or stimulation. The aim of this study is to compare …

50 years of age All Phase 3
N Navin Kaushal, PhD

Caring for Caregivers of Individuals With Alzheimer's Disease

What is this study about? This study is called the EMBRACE Study - A Virtual Community Empowerment Approach Integrating Tradition and Technology for Family Caregivers of Individuals with Alzheimer's Disease. It tests whether a home-based virtual exercise program can reduce depression and anxiety in family caregivers of people living with …

18 - 99 years of age All Phase N/A
J Jessica St. Romain, MA

Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)"

The RAATE proposal is designed to determine the effects of physical activity on risk factors for Alzheimer's Disease in older African American adults. The study will compare a physical activity program to an active control group. There are three main objectives of the protocol: 1) to determine if a physical …

60 years of age All Phase N/A
D Dr Gundersen, MBChB

Alzheimer's Disease and Faecal Microbiota Transplantation -a Pilot Study

The goal of this study is to assess the feasibility and safety of faecal microbiota transplantation for Alzheimer's disease.

18 years of age All Phase 1

A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis

The purpose of this Phase 1 study is to evaluate the safety and tolerability of a new investigational drug called SSGJ-716 in healthy adults and in participants with moderate-to-severe atopic dermatitis (AD). The study has two parts. The first part (Single Ascending Dose, SAD) will enroll healthy adults.The second part …

18 - 45 years of age All Phase 1
G Gaoting Ma

The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease

This study is divided into two phases: a dose-escalation phase and an expansion cohort phase. The dose-escalation phase is a single-center study, while the expansion cohort phase is a multicenter, prospective, randomized, double-blind, placebo-controlled study.

50 years of age All Phase 1/2
M Maria Stefania De Simone, Dr

REducing the Risk of COgnitive DEcline ad Dementia in Patients With Subjective Cognitive Decline Through an Immersive Virtual Reality and Telemedicine-based Multi-component Intervention: the SCD-ReCODED Study

Older adults with subjective cognitive decline (SCD) are at high risk of developing dementia and frequently experience subclinical symptoms (e.g., anxiety, depression) which are themselves associated with dementia and cognitive decline risk. To date, the lack of effective disease-modifying treatments, along with the reliable identification of modifiable lifestyle risk factors …

55 - 80 years of age All Phase N/A
C Chiu Wing CHU, MBChB, MD

Modelling Tau Distribution From DTI With Generative Adversarial Network for Alzheimer's Disease Diagnosis

The most significant impact of this project is to propose for the first time a novel generative adversarial network (GAN), as one kind of deep learning architecture, to automatically generate synthetic PET images reflecting tau deposition, from brain DTI images. If successful, this framework will become the most state-of-the-art approach …

55 years of age All Phase N/A

MIMA Pilot Study: MIcrostructure of the Medial Temporal Lobe in Early Alzheimer's Disease

Patients with Mild Cognitive Impairment (MCI) or Subjective Cognitive Decline (SCD) may or may not develop Alzheimer's disease (AD) dementia. Yet identifying patients at risk is crucial: delaying the onset of the disease by 5 years could reduce prevalence by 50%. To achieve this, we need affordable biomarkers combined with …

50 - 80 years of age All Phase N/A

Biomarkers of Sleep-wake Cycle in Prodromal Alzheimer's Disease: Role in Cognitive Decline?

Alzheimer's disease (AD) is characterised by a progressive loss of memory and cognitive function. In the early stages of AD, there is a progressive accumulation of molecules: β-amyloid peptides (Aβ) in the brain. There is a link between the accumulation of Aβ peptides and the deterioration of sleep, but current …

50 - 85 years of age All Phase N/A

Simplify language using AI